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Aims: This study aimed to evaluate whether the pronounced elevation in blood pressure during severe
hypoglycemia is associated with subsequent renal insufﬁciency.
Methods:We conducted a 3-year cohort study to assess the clinical course of renal function in type 2 diabetes
patients with or without blood pressure surge during severe hypoglycemia.
Results: Of 111 type 2 diabetes patients with severe hypoglycemia, 76 exhibited an extremely high systolic
blood pressure before treatment, whereas 35 demonstrated no such increase (179.1 ± 27.7 mmHg vs.
131.1 ± 20.2 mmHg, P b 0.001). At 12 h after treatment, systolic blood pressure did not differ signiﬁcantly
(131.5 ± 30.7 mmHg vs. 123.5 ± 20.7 mmHg; P = 0.39). The estimated glomerular ﬁltration rate (GFR)
before and at the time of severe hypoglycemia did not signiﬁcantly differ between both groups. A multivariate Cox
proportional hazards regression analysis revealed that blood pressure surge during severe hypoglycemia was
independently associated with a composite outcome of a more than 15 mL/min/1.73 m2 decrease in the estimated
GFR and initiation of chronic dialysis (hazard ratio, 2.68; 95% conﬁdence interval, 1.12–6.38; P = 0.02).
Conclusions:Renal function after severe hypoglycemiawas signiﬁcantlyworse in type 2 diabetes patientswith blood
pressure surge during severe hypoglycemia than those without blood pressure surge.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Severe hypoglycemia can lead to the activation of the sympathoa-
drenal system and the release of counter-regulatory hormones, such
as norepinephrine and epinephrine, resulting in signiﬁcant changes to
peripheral and central blood pressure, elasticity of blood vessels, and
heart rate (Fisher, Gillen, Dargie, Inglis, & Frier, 1987; Hilsted et al.,
1984). In fact, several studies have revealed that patients with
diabetes exhibit blood pressure surges and severe acute hypertension
during severe hypoglycemia (Feldman-Billard, Massin, Meas,
Guillausseau, & Heron, 2010; Tsujimoto et al., 2014). Furthermore,onﬂicts of interest relevant to
docrinology, and Metabolism,
d Medicine, 1-21-1 Toyama,
7181; fax: +81 3 3207 1038.
imoto).
Inc. This is an open access article ubecause there was a delay between the occurrence of severe
hypoglycemia out of the hospital and the initiation of emergency
treatment, the blood pressure surge and severe acute hypertension
might be sustained for several hours in some patients with diabetes.
Although the concept that hypoglycemia may aggravate the
complication of diabetes existed before (Frier & Hilsted, 1985),
several recent studies have reported associations between severe
hypoglycemia and both higher mortality (Krinsley & Grover, 2007;
Tsujimoto et al., 2015a) and an increased risk of cardiovascular
disease (CVD) (Goto, Arah, Goto, Terauchi, & Noda, 2013; Tsujimoto et
al., 2014; Zoungas et al., 2010). In addition, a recent study suggested
that severe hypoglycemia may be associated with an increased risk of
microvascular diseases (Zoungas et al., 2010). Although blood
pressure surge and severe acute hypertension during severe hypo-
glycemia may result in endothelial damage (Lau et al., 1992; Mayer et
al., 2011; Pretre & Von Segesser, 1997; Szczech et al., 2010), leading to
higher risks of microvascular disease, such as renal dysfunction, the
association between hypoglycemia-induced hemodynamic changender the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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to assess whether a blood pressure surge during severe hypoglycemia
can in fact induce or exacerbate renal insufﬁciency in patients with
type 2 diabetes.
2. Methods
2.1. Study design and population
We conducted a cohort study at the National Center for Global
Health and Medicine in Tokyo, Japan. Eligibility criteria included type
2 diabetes patients who had been transported to our hospital by
ambulance and diagnosed with severe hypoglycemia between
January 1, 2006 and March 31, 2012. These patients were assessed
for serum creatinine levels upon arrival at the hospital and at least
once after the initiation of treatment. The patients were followed-up
for 3 years from the day of occurrence of severe hypoglycemia.
Patients on chronic dialysis and with renal transplantation before the
occurrence of the severe hypoglycemic event were excluded from the
study, and those in cardiopulmonary arrest upon arrival were also
excluded. In the present study, severe hypoglycemia was deﬁned as
the presence of any hypoglycemic symptoms that could not be
resolved by the patients themselves and required medical assistance
in the emergency department (American Diabetes Association, 2012).
Blood glucose levels were usually measured at a central laboratory
(81.1%, 90/111); however, in some cases, they were measured using a
blood glucose meter (18.9%, 21/111).
We assessed patient demographic and baseline characteristics,
systolic and diastolic blood pressure levels before and after the
initiation of treatment for severe hypoglycemia, and the clinical
course of renal function for 3 years. All data including the clinical
records and laboratory results of patients were independently
reviewed by at least two diabetologists. At events of disagreement
between the two diabetologists, a third diabetologist was consulted to
resolve the issue. Diabetes was conﬁrmed when the patient had been
previously diagnosed as having diabetes or was being treated with
antidiabetic medicines, and type 2 diabetes was conﬁrmed by a
previous diagnosis or by the absence of a speciﬁc cause of diabetes and
antibodies to glutamic acid decarboxylase. The present study was
approved by the institutional review board of the National Center for
Global Health and Medicine Hospital.
2.2. Blood pressure, renal function, and other measurements
Systolic and diastolic blood pressure levels of the patients were
measured upon arrival and at 12 h after the initiation of treatment,
provided that antihypertensive or vasopressor drugs were not used
during that period. Serum creatinine levels were measured upon
arrival, and estimated glomerular ﬁltration rate (GFR) was calculat-
ed using the following formula, as recommended by the Japanese
Society of Nephrology: estimated GFR (mL/min/1.73 m2) =
194 × Cre − 1.094 × age − 0.287 (×0.739 if the patient is female)
(Matsuo et al., 2009). Glycated hemoglobin (HbA1c) level was
measured at the nearest time within 3 months of arrival.
2.3. Study outcome
In the present study, the primary endpoint measure was the time
to the ﬁrst event of the composite outcome including a decrease of
more than 15 mL/min/1.73 m2 in estimated GFR and the initiation of
chronic dialysis after the occurrence of severe hypoglycemia.
Secondary composite outcomes included the following: 1) a decrease
of more than 15 mL/min/1.73 m2 in estimated GFR from the
occurrence of severe hypoglycemia, the initiation of chronic dialysis,
and death from any cause; 2) a decrease of more than 30 mL/min/
1.73 m2 in estimated GFR and the initiation of chronic dialysis aftersevere hypoglycemia; and 3) the initiation of chronic dialysis. The
outcomes were independently checked from the clinical records by
two diabetologists whowere blinded to the characteristics of patients.
The primary and secondary endpoints were independently reviewed
by at least two diabetologists.
2.4. Statistical methods
Data are presented as number, percentage, mean with standard
deviation, or median with interquartile range. Continuous variables
were compared using t-tests or Wilcoxon rank sum tests. Categorical
variables were compared using chi-square tests or Fisher's exact tests.
The study patients were divided into two groups with or without
blood pressure surge during severe hypoglycemia, according to a
cut-off blood pressure of 160/80 mmHg, which is the approximate
overall median value. Cox proportional hazards models were used to
evaluate the association between blood pressure surge during severe
hypoglycemia and subsequent impairment of renal function. Multi-
variate adjustments weremade for age, sex, preexisting hypertension,
history of ischemic heart disease, blood glucose level upon arrival, and
duration of diabetes. Age was divided according to a cut-off of
70 years, which is the approximate overall median value. Diabetes
duration was divided according to a cut-off of 10 years. Preexisting
hypertension was deﬁned as either a previous diagnosis of hyperten-
sion or the use of antihypertensive medications. History of ischemic
heart diseasewas deﬁned as a history ofmyocardial infarction or angina
pectoris. Kaplan–Meier analyses were used to assess the primary and
secondary endpoints, and groups were compared using the log-rank
test. P values of b0.05 according to two-sided tests were considered to
be statistically signiﬁcant. All analyses were performed using Stata
software, version 11.1 (Stata Corp, College Station, Texas, USA).
3. Results
We screened 59,602 patients who had been brought to the
emergency department of the national center by ambulance. Of these
patients, 293 were diagnosed with type 2 diabetes with severe
hypoglycemia. We excluded one patient receiving chronic dialysis and
181 patients who have not had their serum creatinine levels examined
upon arrival and at least once after the initiation of treatment. The study
criteria were met by 111 patients with severe hypoglycemia. Clinical
characteristics of type 2 diabetes patients upon arrival are presented in
Table 1. Type 2 diabetes patients were divided into two groups with or
without blood pressure surge according to a cut-off blood pressure of
160/80 mmHg as follows: 76 patients with blood pressure surge during
severe hypoglycemia and 35 patients without blood pressure surge. The
proportion of severe hypertension during severe hypoglycemia did not
signiﬁcantly differ in patients with and without preexisting hyperten-
sion (70.0% vs. 61.9%; P = 0.47). Systolic blood pressure levels in type 2
diabetes patients with and without blood pressure surge during severe
hypoglycemia were 179.1 ± 27.7 mmHg and 131.1 ± 20.2 mmHg,
respectively (P b 0.001). About 20% of the type 2 diabetes patients
with blood pressure surge had a systolic blood pressure of more than
200 mmHg (18.4%, 14/76) and some of them had a systolic blood
pressure of more than 230 mmHg (6.6%, 5/76). Estimated GFR of
patients upon arrivalwasnot found to be signiﬁcantlydifferent between
type 2 diabetes patients with and without blood pressure surge during
severe hypoglycemia (57.7 ± 29.1 mL/min/1.73 m2 vs. 55.3 ±
31.1 mL/min/1.73 m2; P = 0.70). In addition, theproportionof patients
with an estimated GFR of b60 mL/min/1.73 m2 did not signiﬁcantly
differ between both groups (53.9% vs. 60.0%; P = 0.55). The estimated
GFR at the nearest time within 3 months before arrival was also not
found to be signiﬁcantly different (55.1 ± 24.2 mL/min/1.73 m2 vs.
57.7 ± 28.2 mL/min/1.73 m2; P = 0.72). Mean age, sex ratio, preva-
lence of preexistinghypertension, use of angiotensin II receptor blockers
or angiotensin converting enzyme inhibitors, blood glucose level upon
Table 1
Baseline clinical characteristics of type 2 diabetes patients with severe hypoglycemia upon arrival.
Characteristics BP surge (+) (n = 76) BP surge (−) (n = 35) P value
Age (y) 76.0 (67.5–83.0) 73.0 (66.0–83.0) 0.59
Women 32.9% 48.6% 0.11
Preexisting hypertensiona 82.9% 77.1% 0.47
Use of ARB/ACE-I 58.7% 51.4% 0.47
History of ischemic heart diseaseb 6.6% 2.9% 0.25
Blood glucose upon arrival (mg/dL) 35.8 ± 17.9 32.7 ± 15.4 0.37
HbA1c (%) (n = 17)c 6.7 ± 1.1 6.6 ± 1.1 0.54
Duration of diabetes (y) (n = 95) 15.0 (8.0–23.0) 17.0 (6.0–24.0) 0.88
≥10 74.2% 60.6% 0.17
Cause of severe hypoglycemia
Insulin or sulfonylureas 88.0% 88.6% 0.93
Estimated GFR (mL/min/1.73 m2) upon arrivald 57.7 ± 29.1 55.3 ± 31.1 0.70
Data are presented as number, percentage, mean (standard deviation), or median (interquartile range). HT, hypertension; ARB, angiotensin II receptor blockers; ACE-I, angiotensin
converting enzyme inhibitors; CCB, calcium channel blockers; HbA1c, glycated hemoglobin; GFR, glomerular ﬁltration rate.
SI conversion factors: To convert blood glucose to mmol/L, multiply by 0.0555; creatinine to μmol/L, multiply by 88.4.
a Preexisting hypertension was deﬁned as previous diagnosis of hypertension or the use of antihypertensive medications.
b History of ischemic heart disease was deﬁned as a history of myocardial infarction or angina pectoris.
c HbA1c level was measured at the nearest time within three months of arrival. HbA1c: 6.7% = 50 mmoL/moL and 6.6% = 49 mmoL/moL.
d Estimated GFR was calculated using the following formula: estimated GFR (mL/min/1.73 m2) = 194 × Cre − 1.094 × age − 0.287 (×0.739 if the patient was a female).
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signiﬁcantly different between the type 2 diabetes patients with and
without blood pressure surge during severe hypoglycemia. All study
patients were initially administered with intravenous glucose for the
treatment of severe hypoglycemia.
Fig. 1 shows the systolic and diastolic blood pressures before and
12 h after the initiation of treatment for severe hypoglycemia. Although
systolic blood pressure during severe hypoglycemia was signiﬁcantly
different, at 12 h after treatment, systolic blood pressure did not differ
signiﬁcantly between type 2 diabetes patients with and without blood
pressure surge (131.5 ± 30.7 mmHg vs. 123.5 ±20.7 mmHg; P =
0.39). Diastolic blood pressure levels were also found to be similar.
The unadjusted cumulative rate of the composite outcome including a
decrease of more than 15 mL/min/1.73 m2 in estimated GFR and the
initiation of chronic dialysis was found to be signiﬁcantly higher in type 2
diabetes patients with blood pressure surge than in those without blood
pressure surge (hazard ratio [HR], 2.22; 95% conﬁdence interval [CI], 1.01–
4.89; P = 0.04). Kaplan–Meier survival curves for these composite events
are shown in Fig. 2. A multivariate Cox proportional hazards regression
analysis revealed that blood pressure surge during severe hypoglycemia
was independently associatedwith these composite events (HR, 2.68; 95%
CI, 1.12–6.38; P = 0.02; Table 2). Even when the use of angiotensin II
receptor blockers or angiotensin converting enzyme inhibitors was
included in multivariate analysis, blood pressure surge during severe
hypoglycemiawas independently associatedwith these composite events
(HR, 2.67; 95%CI, 1.12–6.34; P = 0.02). In addition, itwas revealed by the
multivariate Cox proportional hazards regression analysis that the
composite outcome including a decrease of more than 15 mL/min/
1.73 m2 inestimatedGFR, the initiationof chronicdialysis, anddeath from
any cause was signiﬁcantly associated with blood pressure surge during
severe hypoglycemia (HR, 2.28; 95% CI, 1.03–5.03; P = 0.04) (Table 3).
Similarly, the composite outcome including a decrease of more than
30 mL/min/1.73 m2 in estimatedGFRand the initiation of chronic dialysis
was also signiﬁcantly associated with blood pressure surge during severe
hypoglycemia (HR, 3.74; 95% CI, 1.00–13.91; P = 0.04) (Supplemental
Table 1). The incidence of chronic dialysis was not signiﬁcantly different
between type 2 diabetes patients with (n = 4) and without (n = 1)
blood pressure surge during severe hypoglycemia (5.6% vs. 3.0%;
P N 0.99). No renal transplantation was performed in either group.Fig. 1. Type 2 diabetes patientswere divided into two groupswith orwithout bloodpressure
surge according to a cut-off (systolic blood pressure ≥ 160 mmHg and/or diastolic blood
pressure 80 mmHg). Systolic and diastolic blood pressure levels before and 12 h after
initiation of treatment for severe hypoglycemia with or without blood pressure surge
Systolic (panel A) and diastolic (panel B) blood pressures. Blood pressure levels before and
12 h after the initiation of treatment for severe hypoglycemia were measured in 111 and 39
study patients, respectively.4. Discussion
In the present study, the renal functions before and at the time of
severe hypoglycemia were not found to be signiﬁcantly differentbetween type 2 diabetes patients with and without blood pressure
surge during severe hypoglycemia. However, subsequent renal
function was signiﬁcantly worse in type 2 diabetes patients with
blood pressure surge during severe hypoglycemia. A recent large-
scale meta-analysis revealed that the progression of chronic kidney
disease, which was deﬁned as a reduction of 15 mL/min/1.73 m2 in
the estimated GFR, was associated with an increased risk of all-cause.
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Fig. 2. Kaplan–Meier analysis of the time to the composite outcome including adecrease of
more than 15 mL/min/1.73 m2 in estimatedGFR and the initiation of chronic dialysis after
severe hypoglycemia. GFR, glomerular ﬁltration rate; BP, blood pressure.
Table 3
Multivariate analysis for the composite outcome including a decrease of more than
15 mL/min/1.73 m2 in estimated GFR, the initiation of chronic dialysis, and death from
any cause in type 2 diabetes patients with severe hypoglycemia.
Variables Hazard ratio 95% CI P value
Age ≥70 y 1.31 0.65–2.65 0.44
Women 0.98 0.47–2.04 0.97
Preexisting hypertension 0.87 0.37–2.04 0.76
History of ischemic heart diseasea 0.59 0.17–2.00 0.39
Blood glucose upon arrival (mg/dL) 0.99 0.97–1.01 0.42
Duration of diabetes ≥10 y 0.77 0.38–1.56 0.47
BP surge during severe hypoglycemia 2.28 1.03–5.03 0.04
95% CI, 95% conﬁdence interval; GFR, glomerular ﬁltration rate; BP, blood pressure.
Estimated GFR was calculated using the following formula: estimated GFR (mL/min/
1.73 m2) = 194 × Cre − 1.094 × age − 0.287 (×0.739 if the patient was a female).
a History of ischemic heart disease was deﬁned as a history of myocardial infarction
or angina pectoris.
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reduction of 15 mL/min/1.73 m2 in the estimated GFR observed in
this study has important clinical implications for patients with
diabetes. The present study, to the best of our knowledge, is the
ﬁrst report to reveal the association between blood pressure surge
during severe hypoglycemia and the deterioration of renal function.
The results of the present study strongly suggest that that blood
pressure surge during severe hypoglycemia increases the risk of
vascular damage.
Previous studies suggest that severe hypoglycemia in diabetes is
often associated with an acute surge in blood pressure (Feldman-
Billard et al., 2010; Tsujimoto et al., 2014). Moreover, it was found in a
recent study that the incidence of severe acute hypertension during
hypoglycemia is much higher in patients with type 2 diabetes than in
those with type 1 diabetes, independent of the presence or absence of
preexisting hypertension (Tsujimoto et al., 2014). Because of acute
blood pressure elevation and sustainment of an abnormally high level
of blood pressure after severe hypoglycemia, hypertensive emergency
and a certain level of vascular damage can be developed in type 2
diabetes patients with severe hypoglycemia (Finnerty, 1972;
Tsujimoto et al., 2014). Blood pressure surge during severe hypogly-
cemia is possibly mediated by the activation of the sympathoadrenal
system and the release of catecholamines such as norepinephrine andTable 2
Multivariate analysis for the composite outcome including a decrease of more than
15 mL/min/1.73 m2 in estimated GFR and the initiation of chronic dialysis in type 2
diabetes patients with severe hypoglycemia.
Variables Hazard ratio 95% CI P value
Age ≥70 y 1.39 0.66–2.95 0.38
Women 1.09 0.51–2.34 0.81
Preexisting hypertension 0.75 0.31–1.79 0.52
History of ischemic heart diseasea 0.64 0.18–2.21 0.48
Blood glucose upon arrival (mg/dL) 0.98 0.96–1.01 0.33
Duration of diabetes ≥10 y 0.81 0.37–1.73 0.59
BP surge during severe hypoglycemia 2.68 1.12–6.38 0.02
95% CI, 95% conﬁdence interval; GFR, glomerular ﬁltration rate; BP, blood pressure.
Estimated GFR was calculated using the following formula: estimated GFR (mL/min/
1.73 m2) = 194 × Cre − 1.094 × age − 0.287 (×0.739 if the patient was a female).
a History of ischemic heart disease was deﬁned as a history of myocardial infarction
or angina pectoris.epinephrine. In the present study, the proportion of severe hyper-
tension during severe hypoglycemia was not signiﬁcantly different in
patients with and without preexisting hypertension. Therefore, these
physiological responses to hypoglycemiamight be independent of the
history of hypertension. In addition, beta-adrenergic stimulation leads
to the secretion of renin and the activation of the renin–angiotensin–
aldosterone system. Increased vasoreactivity can be precipitated by
the release of vasoconstricting substances such as angiotensin ΙΙ and
the activation of the renin–angiotensin–aldosterone system appears
to be important in the pathophysiology of severe hypertension
(Ganten et al., 1992; Mullins, Peters, & Ganten, 1990). The increases in
the levels of several hormones such as renin, angiotensin ΙΙ,
aldosterone, and vasopressin vary andmight affect the blood pressure
in patients with severe hypoglycemia to a different extent. We could
speculate that hypoglycemia-induced sympathetic surges might lead
to renal hemodynamics, increase in coagulation and viscosity which
could restrict blood ﬂow to renal tissues, and the activation of
leucocytes and platelets that might encourage thrombosis or release
local factors leading to damage of endothelium (Wright & Frier, 2008).
In addition, acute hypoglycemia itself might have a transient effect on
the renal function, reducing the GFR and the renal plasma ﬂow
(Patrick et al., 1989; Patrick, Hepburn, Swainson, & Frier, 1992).
Moreover, the arterial pressure surge during severe hypoglycemia can
be partially attributed to the existing vascular dysfunction and
damage (Anderson et al., 1996; Celermajer, Sorensen, Bull, Robinson,
& Deanﬁeld, 1994; Iwai et al., 1999; Kosecka, Marshall, Crowe,
Bienenstock, & Perdue, 1994; Vallance, Collier, & Moncada, 1989;
Vaughan & Delanty, 2000; Vaughan & Delanty, 2000). The arterial
stiffness before the severe hypoglycemic episodesmight be associated
with the blood pressure changes and the progressive decline in renal
function.
Furthermore, ﬂuctuations in blood pressure due to severe
hypoglycemia may directly impede renal function (Nakano et al.,
2015; Thompson & Pickering, 2006). Recent studies suggest that
ﬂuctuations in blood pressure are associated with higher levels of
C-reactive protein and interleukin-6 (Poortvliet et al., 2015), and the
inﬂammations may cause arterial damage, including that within the
kidney. There is a high prevalence of CVD in patients with chronic
kidney disease, and the presence of renal dysfunction appears to be an
independent risk factor for poor cardiovascular outcome in type 2
diabetes patients (Sarnak et al., 2003).
Our study had several limitations. First, this was an observational
study that was performed at a single national center. Therefore,
larger-scale multicenter studies are needed to conﬁrm the results
reported in this study. Second, in addition to the limited number of
samples, the missing data might have affected the results of our
statistical analyses and their interpretation. Themissing data included
urine microalbumin levels, information on the presence or absence of
685T. Tsujimoto et al. / Journal of Diabetes and Its Complications 30 (2016) 681–685preexisting diabetic nephropathy, other severe hypoglycemic epi-
sodes, and blood pressure levels prior to severe hypoglycemic events.
No subsequent hypoglycemic episodes were found in the medical
records during the study period. However, we did not prospectively
monitor hypoglycemia, and unknown severe hypoglycemic events
may have occurred. Signiﬁcant renal damage might be caused by not
only a single surge in blood pressure during a period of severe
hypoglycemia but also other blood pressure responses to hypoglyce-
mia including non-severe hypoglycemia. In addition, because the
causal relationship remains unclear, the blood pressure changes
during severe hypoglycemia may reﬂect the severity of underlying
renal pathology. However, no clinical studies have investigated the
association between severe hypoglycemia and renal dysfunction in
type 2 diabetes patients; thus, we suggest that the results of this study
are very important and have clinical implications for the management
of diabetes. Finally, the follow-up period in this study was short; thus,
the study reports only short-term outcomes for renal function.
Therefore, studies with longer follow-up periods are required to
assess the inﬂuence of blood pressure surge during severe hypogly-
cemia on chronic kidney function as well as on microvascular and
macrovascular diseases such as myocardial infarction and stroke.
In conclusion, this study suggests that in type 2 diabetes patients,
renal function was signiﬁcantly worse after severe hypoglycemia with
blood pressure surge, compared with those without blood pressure
surge. These results indicate that in addition to aggressive prevention
of severe hypoglycemic episodes, clinicians who manage patients
with type 2 diabetes should pay more attention to blood pressure
elevations during these episodes. The development and progression of
renal dysfunction in type 2 diabetes patients leads to renal replacement
therapy and is a strong predictor of cardiovascular events (Centers for
Disease Control and Prevention, 2010; Sarnak et al., 2003). Therefore,
type 2 diabetes patients with severe hypoglycemia should be carefully
monitored for blood pressure and subsequent renal function. Although
the prior use of beta-blockers may prevent severe hypertension during
severe hypoglycemia in diabetic patients (Tsujimoto et al., 2015b),
further studies on preventing complications associated with severe
hypoglycemia are necessary. Clinicians must consider the risks and
beneﬁts of glycemic control to reduce severe hypoglycemia for the
further prevention of renal impairment.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.jdiacomp.2016.01.015.
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